awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35208151-05AA2B59-4643-4C84-8C4D-C3B3B02FAF98
Q35208151-05AA2B59-4643-4C84-8C4D-C3B3B02FAF98
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35208151-05AA2B59-4643-4C84-8C4D-C3B3B02FAF98
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
P2860
Q35208151-05AA2B59-4643-4C84-8C4D-C3B3B02FAF98
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35208151-05AA2B59-4643-4C84-8C4D-C3B3B02FAF98
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7a8146cf621b7829cd6422eabee107d001f4c936
P2860
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.